Market Research Logo

Therapies for Resistant and Recurrent Metastatic Cancer

Therapies for Resistant and Recurrent Metastatic Cancer

The global cancer therapeutics market should reach $172.6 billion by 2022 from $121 billion in 2017 at a compound annual growth rate (CAGR) of 7.4%, from 2017 to 2022.

The lung cancer market is expected to grow from $15.7 billion in 2017 to $22.6 billion in 2022 at a CAGR of 7.6% for the period 2017-2022.

The stomach cancer segment of the global cancer therapeutics market is expected to grow from $8.2 billion in 2017 to $11.9 billion in 2022 at a CAGR of 7.7% for the period 2017-2022.


Chapter 1 Introduction
Study Goals and Objectives
Scope of Report
Methodology and Information Sources
Primary Data and Information Gathering
Secondary Data and Information Gathering
Market Share Analysis and Market Forecast Prediction
Geographic Breakdown
Analyst's Credentials
Related BCC Research Reports
Chapter 2 Summary and Highlights
Chapter 3 Incidence, Prevalence and Mortality Statistics for Cancer: A Global Summary
Cancer: The Disease
Cancer: A Statistical Analysis of the Disease Incidence and Prevalence
Regional Patterns of Cancer
The Global Cancer Burden and Worldwide Cancer Risk Factors
Incidence and Prevalence Rates for Major Cancer Types
Europe
North America
Asia-Pacific
Latin and Central America
Middle East/Africa
Tobacco Use and Statistics
Alcohol Abuse and Cancer Statistics
Obesity and Cancer Statistics
Infectious Diseases and Cancer
Inherited Genes/Diseases and Cancer
BRCA1 and BRCA2 Genes
TP53 and PTEN
Sun, Ultraviolet Radiation and Cancer
Hormones and Cancer
Chapter 4 Metastasis and Current Understanding of the Mechanisms of Resistance and Recurrence in Metastatic Cancer
What is Metastatic Cancer
Pathophysiology
Routes of Metastasis
Diagnosis
Classification of Metastasis
Metastasis: Common Sites of Origin
The Lung
The Breast
Melanoma
The Colon
The Kidney
The Prostate
Types of Prostate Cancer
Acinar Adenocarcinoma
Ductal Adenocarcinoma
Transitional Cell (or urothelial) Cancer
Squamous Cell Cancer
Small Cell Prostate Cancer
Other Rare Prostate Cancers
The Pancreas
Other rare types of pancreatic cancer
Pancreatoblastoma
Sarcomas of the Pancreas
Lymphoma
The Liver
Types of primary liver cancer
Hepatocellular Carcinoma (Hepatocellular Cancer) (HCC)
Intrahepatic Cholangiocarcinoma (Bile Duct Cancer)
Angiosarcoma and Hemangiosarcoma
Hepatoblastoma
Secondary Liver Cancer (Metastatic Liver Cancer)
The Cervix
Essential Understanding in Cancer Biology
Current Understanding of Mechanisms of Resistance and Recurrence in Metastatic Cancer
Inherent Resistance
Acquired Resistance
Altered Membrane Transport
Enhanced DNA Repair
Apoptotic Pathway Defects
Alteration of Target Molecules
Protein and Pathway Mechanisms
Genome Alterations (Gene Amplification and Deletion)
Epigenetic Modifications
Chapter 5 Cancer: Current Therapy Strategies
General Treatment Strategies
Cancer Drug Treatment Strategies
Hormonal Cancer Drug Therapy
Targeted Biologic Therapy
Cytotoxic Cancer Drugs Therapies
Surgery for Cancer
Radiotherapy for Cancer
Cytotoxic Cancer Chemotherapy
Cytotoxic Cancer Drugs Classification
Alkylating and Alkylating-Like Agents
Antimetabolites
Antitumor Antibiotics
Plant alkaloids
Miscellaneous agents
Hormone-based Cancer Drugs
Targeted Biologic Therapy
Monoclonal Antibodies (MAB)
Types of Monoclonal Antibodies
Naked Monoclonal Antibodies
Conjugated Monoclonal Antibodies
Radiolabeled Antibodies
Chemolabeled Antibodies
Bispecific Monoclonal Antibodies
Drugs that Target PD-1 or PD-L1
PD-1 Inhibitors
PD-L1 inhibitors
Drugs that target CTLA-4
Cancer Growth Blockers
mTOR Inhibitors
Second Generation mTOR Inhibitors
Proteasome Inhibitors
Phosphoinositide 3-Kinase Inhibitors (PI3K Inhibitors)
Idelalisib (Zydelig) (Gilead Sciences)
Histone Deacetylase Inhibitors
Tyrosine Kinase Inhibitors (TKIs)
Hedgehog Pathway Blockers
Blood Cell Growth Factors
Cancer Vaccines
Gene Therapy
Drugs that Block Cancer Blood Vessel Growth (Antiangiogenics)
Cytokines (Interferon and Interleukin 2)
Personalized Cancer Therapy (Precision Medicine)
Chapter 6 Metastatic Cancer Treatment Options by Tumor Origin
Bladder
Surgery
Radiation Therapy
Chemotherapy
Immunotherapy
Avelumab (Bavencio)
Nivolumab (Opdivo)
Pembrolizumab (Keytruda)
Durvalumab (Imfinzi)
Atezolizumab (Tecentriq)
Breast
Hormone Therapy
Blocking Estrogen's Effects
Selective Estrogen Receptor Modulators (SERMs)
Other Antiestrogen Drugs
Blocking Estrogen Production
Blocking Ovarian Function
Targeted Therapy
Chemotherapy and Radiology
Chemotherapy
Anthracyclines
Alkylating Agents
Taxanes
Other Microtubule Inhibitors
Antimetabolites
Platinum-based Chemotherapy
Chemotherapy Combinations
Radiation Therapy
Other Treatment Options
Surgery
Colorectal
Standard Treatment Options for Stage IV and Recurrent Rectal Cancer
Surgery with or without Chemotherapy or Radiation Therapy
First-line Chemotherapy and Targeted Therapy
Fluorouracil (5-FU)
Irinotecan
Oxaliplatin (Eloxatin)
Capecitabine
FOLFOXIRI (Irinotecan, Oxaliplatin, Leucovorin [LV], and 5-FU)
Bevacizumab
Cetuximab
Aflibercept
Ramucirumab
Panitumumab
Anti-EGFR Antibodies
Regorafenib
TAS-102
Second-line Chemotherapy
Palliative Therapy
Treatment of Liver Metastasis
Standard Treatment Options for Stage IV and Recurrent Colon Cancer
Kidney
Renal Cell Cancer (RCC) Treatment
Surgery
Radiation Therapy
Chemotherapy
Immunotherapy or Biologic Therapy
Targeted Therapy
Anti-angiogenesis Therapy
Tyrosine Kinase Inhibitors (TKIs)
mTOR Inhibitors
Transitional Cell Cancer (TCC) of the Renal Pelvis and Ureter
Lung
Treatment Options for Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC)
Surgery
Radiation therapy
Chemotherapy
Types of Chemotherapy
Non-Small Cell Lung Cancer (NSCLC)
Small Cell Lung Cancer (SCLC)
Targeted Therapy
Monoclonal Antibodies
Tyrosine Kinase Inhibitors
Treatments for Metastatic Lung Cancer to the Liver
Research Options and Objectives
Melanoma
Treatments for Stage IV Melanoma, Recurrent and Metastatic Melanoma
Immunotherapy
Immune Checkpoint Inhibitor Therapy
Targeted Therapy
Signal Transduction Inhibitor Therapy
Oncolytic Virus Therapy
Angiogenesis Inhibitors
Ovary
Treatments for Stage IV Melanoma, Recurrent and Metastatic Melanoma
Pancreas
Prostate
Radiation Therapy
Hormone Therapy
Androgen Deprivation, an Adjuvant Therapy
Immunotherapy/Therapeutic Vaccines
Vascular-Targeted Photodynamic Therapy
Stomach
Surgery
Chemotherapy
Radiation Therapy
Chemoradiation Therapy
Targeted Therapy
Thyroid
Surgery
Radiation Therapy, Including Radioactive Iodine Therapy
External Beam Radiation Therapy for Thyroid Cancer
Targeted Therapy
Uterus
Chapter 7 Global Market for Cancer Therapeutics by Cancer Type
Global Cancer Therapeutics Market, by Cancer Type
Market Dynamics
Global Market Drivers
Increasing Cancer Prevalence Rates and Aging Population
Rising Awareness among People with Cancer and its Treatment
Continued Emphasis on R&D activities in Cancer and Treatment Technologies
Promised Potential of Alternative Therapies, e.g., Gene Therapy and Personalized Medicine
Greater Understanding of the Genetic Base of Individual Cancers
Fast Track Designation of Approvals and Clinical Trials
Introduction of a Range of Initiatives to Support New and Innovative Therapeutics for Cancer
The Cancer Moonshot
The Genomic Data Commons
The National Clinical Trials Network (NCTN)
The RAS Initiative
Collaborations, Partnerships, and Acquisitions having Major Impact on Industry Strategic Approach
Global Market Restraints
Requirement to Provide Sufficient Data and Proof of Efficacy to obtain Reimbursement for New and Innovative Technologies
Unpredictability and Uncertainty of Clinical Trials
High Capital Investment and Low Benefit-Cost Ratio Risks Associated with Healthcare Technology Related Development Programs
Patents Expiration of Leading Drugs, Commercialization of Biosimilars and Decline in ASPs
Highly Competitive Market Crowded with Proprietary Technologies
Regional Cancer Drugs Market Assessment: North America
Selected Market Drivers: North America
The Increasing Burden of Cancer in the United States
Standardized Combination Chemotherapy Contributing to Increased Survival and Cure Rates
Increased Survival Rates for Metastatic Breast Cancer (MBC) in the United States
Patient Assistance Programs (PAPs)
Increased Rates of Metastatic Prostate Cancer Cases in the United States
Selected Market Restraints: North America
Restricted and Increased Control of Access to Cancer Care After ACA
Increased Cost Sharing
The Current Product Approval System Stifles Innovation
Selected Country: Cancer Drugs Market, by Cancer Type
United States
Canada
Regional Cancer Drugs Market Assessment: Europe
Selected Market Drivers: Europe
Growing Aging Population in Europe
Latest Technological Advances and Innovations Helping to Develop Cancer Therapy Market in Europe
Development of Combination Chemotherapy
Advances in Hormonal Therapy
Antiangiogenesis Agents
Emergence of Personalized Medicine
Acquisitions and Collaborations - Bolt-On Strategies Driving the Market Growth
Selected Market Restraints: Europe
Austerity Measures have been Introduced Throughout Europe
Increased Competitive Product Pricing and Mandatory Tendering Regarded as a Major Market Restraint
Revolutionary Cancer Treatments in Europe
Continued Market Appearance of Generics and Biosimilars
Selected Country: Cancer Drugs Market, by Cancer Type
France
Germany
Other European Countries
Regional Cancer Drugs Market Assessment: Asia-Pacific
Selected Market Drivers: Asia-Pacific
Aging Demographics in Japan
Growth in the Indian Market
The Impact of the Chinese Government's 2012 Healthcare Reform Plan on the Diagnostics Market
China: Cancer Rates Growing ''Ferociously''
Selected Market Restraints: Asia-Pacific
Specific Market Restraints Relating to China
Specific Market Restraints Relating to India
Specific Market Restraints Relating to Japan
Selected Country: Cancer Drugs Market, by Cancer Type
Regional Cancer Drugs Market Assessment: Central and Latin America
Selected Market Drivers: Central and Latin America
Significant Market Growth Opportunities in Brazil
Growth in Private Healthcare and Private Insurance Plans
Expansion and Modernization of Top Private Hospitals
Government Support to Boost Brazil Healthcare Sector
Expansion of Pharmaceutical Healthcare Opportunities in Mexico
Introduction of Tax-funded Universal Health Coverage Throughout Latin America
Selected Market Restraints: Central and Latin America
Diverse Regulatory Environment Constraints Latin American Pharmaceutical Market
Challenges Associated with Local Business Practices and Cultural Conditions in Brazil
Limited Reimbursement System in Brazil
Pricing Issues
Selected Country: Cancer Drugs Market, by Cancer Type
Regional Cancer Drugs Market Assessment: Middle East/Africa
Selected Market Drivers: Middle East/Africa
Substantial Financial Support for Healthcare in Saudi Arabia
South Africa's Political Stability and Improved Economic Outlook Helps Support Growth in the Healthcare Market
Selected Market Restraints: Middle East/Africa
Limited Infrastructure Capacity Throughout Africa
Inherent Political and Economic Issues Constrain the Provision of Healthcare in Africa
Poor Distribution Structure and Networks in Africa
Medical Tourism to India for African Patients Requiring High-Frequency Ultrasound for Prostate Cancer
Selected Region: Cancer Drugs Market, by Cancer Type
Chapter 8 Regulatory and Legislative Requirements
The United States
Canada
Europe
Mutual Recognition Procedure (MRP)
Decentralized Procedure (DCP)
Centralized Procedure (CP)
Japan
China
India
South Korea
Brazil
Argentina
Mexico
South Africa
Saudi Arabia
Marketing Authorization System
Pharmaceutical Reimbursement Approval Process in Japan
Overview of the Healthcare System
Pharmaceutical Regulatory and Legislative Developments: China
Overview of the Healthcare System
National Level
State Level
Regional Level
District Level
Sub-Divisional/Taluka Level
Community Level
Primary Health Center's (PHC) Level
Sub Health Center (SHC) Level
Hospital Resources
Population Statistics
Pharmaceutical Regulatory and Legislative Developments: India
Regulatory and Legislative Requirements
Pharmaceutical Regulatory and Legislative Developments: South Korea
Pharmaceutical Reimbursement: South Korea
Market Entry and Reimbursement of Pharmaceuticals
Background
Government-funded Public Health Sector
Social Health Insurance Sector
Private Sector
Regulatory and Legislative Requirements
Regulation and Regulation Governing Medical Devices and Drugs in Mexico
Health Insurance Structure in Mexico
Instituto Mexicano del Seguro Social (IMSS)
Seguro Popular (SP) or “People’s Insurance”
Regulatory Requirements: South Africa
Health Insurance Structure: South Africa
Reimbursement of Pharmaceuticals: South Africa
The Public Healthcare System
Primary Healthcare Services
Secondary and Tertiary Healthcare Services
The Private Healthcare Sector
Pharmaceutical Regulatory Requirements: Saudi Arabia
Chapter 9 Patent Review/ New Developments
Filed Patents by Clinical Application
Filed Patents and Expiry Dates for Major Products by Leading Suppliers
Filed Patents and Expiry Dates for Other Products and Suppliers
Filed Patents Cited for Metastatic Breast Cancer (01-01-2016 to 05-26-2017)
Filed Patents Cited for Metastatic Lung Cancer (11-05-2015 to 05-11-2017)
Filed Patents Cited for Other Cancer Types (11-05-2015 to 06-07-2017)
Pfizer Inc.
Merck & Co.
Johnson & Johnson
F Hoffman La Roche
Sanofi S.A.
Novartis AG
Gleevec/Glivec
Tasigna
Sandostatin
Sandostatin LAR
Afinitor/Votubia and Afinitor Disperz/Votubia Dispersible Tablets
Exjade
Jadenu
Votrient (Pazopanib)
Tafinlar (Dabrafenib)
Mekinist (Trametinib)
Promacta/Revolade
Zykadia (LDK378, ceritinib)
Farydak
Abbvie Inc.
Imbruvica (Ibrutinib)
Venclexta (venetoclax)
AstraZeneca PLC
Iressa (Gefitinib)
Faslodex (Fulvestrant)
Lynparza
Tagrisso (Osimertinib)
Zoladex
Caprelsa (Vandetanib)
Gilead Sciences
Targeting Breakpoint Cluster Region-Abelson (BCR-ABL)
Targeting Epidermal Growth Factor Receptor (EGFR/ERBB1)
Targeting Vascular Endothelial Growth Factor Receptor (VEGFR), PDGFR and Ret Proto-Oncogene (RET)
Latest Approved Immunotherapy Drugs
Ponatinib (Iclusig) Incyte Corporation
Sprycel (Dasatinib) (Bristol-Myers Squibb)
Giotrif (Afatinib) (Boehringer Ingelheim)
Tyverb (Lapatinib) (Novartis)
Cometriq (Cabozantinib) (Exelixis, Inc)
Vargatef/Ofev (Nintedanib) (Boehringer-Ingelheim)
Stivarga (Regorafenib) (Bayer Healthcare)
Nexavar (Sorafenib) (Bayer Healthcare)
Chapter 10 Company Profiles
The Top 10 Multinational Pharmaceutical Companies
ABBVIE INC.
AMGEN
ASTRAZENECA PLC
GILEAD SCIENCES
F HOFFMAN LA ROCHE AG
JOHNSON & JOHNSON
MERCK & CO., INC.
NOVARTIS AG
PFIZER, INC.
SANOFI S.A.
Other Key Pharmaceutical Company Suppliers
ARRAY BIOPHARMA INC.
ASTELLAS PHARMA INC.
BAYER HEALTHCARE
BIOGEN, INC.
BRISTOL-MYERS SQUIBB
CASCADIAN THERAPEUTICS INC.
CELGENE CORPORATION
CELLDEX THERAPEUTICS, INC.
EISAI CO., LTD.
ELI LILLY AND COMPANY
GALENA BIOPHARMA, INC.
GLAXOSMITHKLINE
IMMUNOCELLULAR THERAPEUTICS, LTD.
IMMUNOGEN, INC.
INCYTE CORPORATION
INFINITY PHARMACEUTICALS, INC.
NEW LINK GENETICS CORP.
OTSUKA HOLDINGS CO., LTD.
TAKEDA PHARMACEUTICALS
REGENERON PHARMACEUTICALS, INC.
VERASTEM INC.
Chapter 11 Company Contact Details
Company Addresses and Contact Details
Government Regulatory Agencies and Professional Organizations
Commonly Used Acronyms Associated with Metastatic and Recurrent Cancer
Stage I and Stage II Endometrial Cancer
Chemotherapy
Hormone Therapy
Biologic Therapy
Further Research and Clinical Trials
Low-risk Endometrial Cancer (Grade 1 or Grade 2)
High-risk Endometrial Cancer (Grade 3)
Stage III, Stage IV, and Recurrent Endometrial Cancer
Rapamycin (mTOR) inhibitors
Bevacizumab
Health Insurance Structure: Saudi Arabia
Summary Table : Global Cancer Therapeutics Market, by Cancer Type, Through 2022
Table 1 : Global Statistics: Estimated Incidence, Mortality and Five-Year Prevalence, 2012
Table 2 : Global Statistics: Estimated Incidence, Mortality and Five-Year Prevalence (in Men and Women Combined), by Cancer Type, 2012
Table 3 : Global Statistics: Estimated Incidence, Mortality and Five-Year Prevalence (Men), by Cancer Type, 2012
Table 4 : Global Statistics: Estimated Incidence, Mortality and Five-Year Prevalence (Women), by Cancer Type, 2012
Table 5 : Estimated Number of New Cancer Cases, by Sex: The United States, 2017
Table 6 : Estimated Number of Deaths from Cancer, by Sex: The United States, 2017
Table 7 : Common Sites for Metastasis
Table 8 : Cancer Treatment Options
Table 9 : Cancer Drug Treatment Classification
Table 10 : Advantages of Minimally Invasive Surgery
Table 11 : FDA Approved Therapeutic Monoclonal Antibodies used to Treat Cancer, 1997-2017
Table 12 : Approved Tyrosine kinase inhibitors (TKIs) used to Treat Cancer
Table 13 : Common Sites for Metastasis
Table 14 : Common Chemotherapeutic Agents for Recurrent and Metastatic Breast Cancer
Table 15 : Chemotherapeutic Combinations for Recurrent and Metastatic Breast Cancer
Table 16 : Treatment Options for Stage IV and Recurrent Colon Cancer
Table 17 : Drugs Approved for the Treatment of Lung Cancer
Table 18 : Drugs Approved for the Treatment of Melanoma
Table 19 : Drugs Approved for Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Table 20 : Combination Drugs Approved for Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Table 21 : Drugs Approved for Pancreatic Cancer
Table 22 : Drugs Approved for Pancreatic Cancer
Table 23 : Hormone Therapy for Prostate Cancer
Table 24 : Drugs Approved for Prostate Cancer
Table 25 : Drugs Approved for Stomach (Gastric) Cancer
Table 26 : Drugs Combinations Approved for Stomach (Gastric) Cancer
Table 27 : Drugs Approved for Gastroenteropancreatic Neuroendocrine Tumors
Table 28 : Treatment Option Overview for Thyroid Cancer
Table 29 : Drugs Approved for Thyroid Cancer
Table 30 : Treatment Option Overview for Endometrial Cancer
Table 31 : Global Cancer Therapeutics Market, Through 2022
Table 32 : Global Cancer Therapeutics Market, by Cancer Type, Through 2022
Table 33 : Global Cancer Therapeutics Market and Market Share, by Cancer Type, 2017
Table 34 : North American Cancer Therapeutics Market, Through 2022
Table 35 : North American Therapeutics Market, by Cancer Type, Through 2022
Table 36 : North American Market Share, by Individual Country, 2017
Table 37 : United States' Therapeutics Market, by Cancer Type, Through 2022
Table 38 : Canadian Therapeutics Market, by Cancer Type, Through 2022
Table 39 : European Cancer Therapeutics Market, Through 2022
Table 40 : European Therapeutics Market, by Cancer Type, Through 2022
Table 41 : European Market Share, by Individual Country, 2017
Table 42 : France's Therapeutics Market, by Cancer Type, Through 2022
Table 43 : Germany's Therapeutics Market, by Cancer Type, Through 2022
Table 44 : Italy's Therapeutics Market, by Cancer Type, Through 2022
Table 45 : Spain's Therapeutics Market, by Cancer Type, Through 2022
Table 46 : United Kingdom's Therapeutics Market, by Cancer Type, Through 2022
Table 47 : Benelux's Therapeutics Market, by Cancer Type, Through 2022
Table 48 : Scandinavia's Therapeutics Market, by Cancer Type, Through 2022
Table 49 : Rest of Europe's Therapeutics Market, by Cancer Type, Through 2022
Table 50 : Asia-Pacific Cancer Therapeutics Market, Through 2022
Table 51 : Asia-Pacific Therapeutics Market, by Cancer Type, Through 2022
Table 52 : Asia-Pacific Market Share, by Individual Country, 2017
Table 53 : Japanese Therapeutics Market, by Cancer Type, Through 2022
Table 54 : Chinese Therapeutics Market, by Cancer Type, Through 2022
Table 55 : Indian Therapeutics Market, by Cancer Type, Through 2022
Table 56 : South Korean Therapeutics Market, by Cancer Type, Through 2022
Table 57 : Taiwan's Therapeutics Market, by Cancer Type, Through 2022
Table 58 : Rest of Asia-Pacific Therapeutics Market, by Cancer Type, Through 2022
Table 59 : Central and Latin American Cancer Therapeutics Market, Through 2022
Table 60 : Central and Latin American Therapeutics Market, by Cancer Type, Through 2022
Table 61 : Central and Latin American Market Share, by Individual Country, 2017
Table 62 : Argentina's Therapeutics Market, by Cancer Type, Through 2022
Table 63 : Brazil's Therapeutics Market, by Cancer Type, Through 2022
Table 64 : Chile's Therapeutics Market, by Cancer Type, Through 2022
Table 65 : Mexico's Therapeutics Market, by Cancer Type, Through 2022
Table 66 : Rest of Central and Latin America's Therapeutics Market, by Cancer Type, Through 2022
Table 67 : Middle East/Africa's Cancer Therapeutics Market, Through 2022
Table 68 : Middle East/Africa's Therapeutics Market, by Cancer Type, Through 2022
Table 69 : Middle East/Africa's Market Share, by Individual Country, 2017
Table 70 : Middle East's Therapeutics Market, by Cancer Type, Through 2022
Table 71 : African Therapeutics Market, by Cancer Type, Through 2022
Table 72 : Overview of Healthcare in India
Table 73 : Latest Patent Publications Cited Relating to Metastatic Breast Cancer, 2016-May 2017
Table 74 : Latest Patent Publications Cited Relating to Metastatic Prostate Cancer, 2015-May 2017
Table 75 : Latest Patent Publications Cited Relating to Metastatic Lung Cancer, 2015-March 2017
Table 76 : Latest Patent Publications Cited Relating to Other Metastatic Cancers, 2015-March 2017
Table 77 : Pfizer Inc. Patent Expiry Dates for Leading Cancer Drugs
Table 78 : Merck & Co Patent Status Leading Oncology Products
Table 79 : Johnson & Johnson Patent Status Leading Oncology Products
Table 80 : F Hoffman La Roche Patent Status Leading Oncology Products
Table 81 : Sanofi S.A. Patent Status Leading Oncology Products
Table 82 : AstraZeneca plc Patent Status Leading Oncology Products
Table 83 : Top 10 Pharmaceutical Companies 2017
Table 84 : Abbvie Inc. Company Financials, by Product, 2014-2016
Table 85 : Amgen Company Financials, 2014-2016
Table 86 : Amgen Company Financials, by Product, 2014-2016
Table 87 : AstraZeneca plc Company Financials, by Therapeutic Product Group, 2014-2016
Table 88 : AstraZeneca plc Company Financials, by Oncology Product Group, 2014-2016
Table 89 : Gilead Sciences Summary Financials, 2014-2016
Table 90 : Gilead Sciences Product Pipeline
Table 91 : F Hoffman La Roche Summary Financials, 2014-2016
Table 92 : F Hoffman La Roche Pharmaceutical Division Financials, 2014-2016
Table 93 : F Hoffman La Roche Pharmaceutical Division Oncology Product Sales, 2014-2016
Table 94 : Johnson & Johnson Summary Financials, 2014-2016
Table 95 : Johnson & Johnson Pharmaceutical Therapeutic Area Product Sales, 2014-2016
Table 96 : Johnson & Johnson Oncology Product Sales, 2014-2016
Table 97 : Merck & Co Inc. Therapeutic Area Product Sales, 2014-2016
Table 98 : Merck & Co Oncology Product Sales, 2014-2016
Table 99 : Novartis AG Summary Financials, 2014-2016
Table 100 : Novartis AG Summary Financials, 2014-2016
Table 101 : Novartis AG Major Development Projects
Table 102 : Pfizer, Inc. Summary Financials, 2014-2016
Table 103 : Pfizer, Inc. Innovative Health (IH) Division Financials, 2014-2016
Table 104 : Pfizer, Inc. Innovative Health (IH) Division Oncology Product Sales, 2014-2016
Table 105 : Sanofi S.A. Summary Financials, 2014-2016
Table 106 : Sanofi S.A. Oncology Product Sales, 2014-2016
Table 107 : Array Biopharma Inc. Clinical Stage Drug Portfolio
Table 108 : Astellas Pharma Inc Innovative Health (IH) Division Oncology Product Sales, 2014-2016
Table 109 : Bayer AG Company Financials, 2014-2016
Table 110 : Bayer AG Oncology Product Sales, 2014-2016
Table 111 : Biogen, Inc. Summary Company Financials, 2014-2016
Table 112 : Bristol-Myers Squibb Segment Product Sales, 2014-2016
Table 113 : Bristol-Myers Squibb Oncology Product Sales, 2014-2016
Table 114 : Celgene Corporation Financial Summary, 2014-2016
Table 115 : Eisai Co., Ltd. Financial Summary, 2014-2016
Table 116 : Eisai Co., Ltd Oncology Product Sales, 2014-2016
Table 117 : Eli Lilly and Company Selected Product Sales, 2014-2016
Table 118 : GlaxoSmithKline Financial Summary by Segment, 2014-2016
Table 119 : GlaxoSmithKline Pharmaceuticals Turnover by Therapeutic Area, 2014-2016
Table 120 : GlaxoSmithKline Oncology Product Pipeline
Table 121 : Incyte Corporation Company Revenues, 2014-2016
Table 122 : Tekada Company Revenues, 2014-2016
Table 123 : Regeneron Pharmaceuticals, Inc. Company Revenues, 2014-2016
Table 124 : Company Addresses and Contact Details
Table 125 : Government Regulatory Agencies and Professional Organizations associated with Metastatic and Recurrent Cancer
Table 126 : Commonly Used Acronyms Associated with Metastatic and Recurrent Cancer
Summary Figure : Global Cancer Therapeutics Market Share, by Cancer Type, 2017
Figure 1 : Estimated World Cancer Incidence Proportions, by Cancer Type, in Men and Women Combined, 2012
Figure 2 : Estimated World Cancer Incidence Proportions, by Cancer Type, in Men, 2012
Figure 3 : Estimated World Cancer Incidence Proportions, by Cancer Type, in Women, 2012
Figure 4 : Metastatic Sites for Common Cancers
Figure 5 : Schematic of Acquired Resistance Mechanisms
Figure 6 : The Intrinsic and Extrinsic Pathways of Apoptosis
Figure 7 : Managing Locally Advanced or Metastatic Bladder Cancer
Figure 8 : Global Market Share, by Cancer Type, 2017
Figure 9 : All Cancers, Average Number of New Cases per Year and Age-Specific Incidence Rates, U.K. 2012-2014
Figure 10 : North American Market Share, by Individual Country, 2017
Figure 11 : Estimates and Projections of Metastatic Breast Cancer (MBC) Prevalence in the United States, 1990-2020
Figure 12 : European Market Share, by Individual Country, 2017
Figure 13 : Asia-Pacific's Market Share, by Individual Country, 2017
Figure 14 : Central and Latin American Market Share, by Individual Country, 2017
Figure 15 : Middle East/Africa's Market Share, by Individual Country, 2017
Figure 16 : Drug Discovery and Development Time Line
Figure 17 : Mutual Recognition Procedure
Figure 18 : Decentralized Procedure
Figure 19 : Japanese Drug Funding/Reimbursement Approval Procedure
Figure 20 : The Chinese Healthcare System
Figure 21 : Argentina: Regulatory Drug Approval Procedure Standard Review 120-240 Business Days* for Approval**
Figure 22 : Current Structure of the Health Care Sectors in Saudi Arabia

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report